 |
|
|
| |
TURQUOISE-I STUDY: USE OF OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN IN PATIENTS WITH HCV/HIV-1 CO-INFECTION ON STABLE DARUNAVIR-CONTAINING ANTIRETROVIRAL THERAPY
|
| |
| |
Reported by Jules Levin
15th European AIDS Conference · Barcelona, Spain · 23 October 2015
Peter Ruane,1 Oluwatoyin Adeyemi,2 Roger Trinh,3 Jacob Lalezari,4
Laveeza Bhatti,5 Jihad Slim,6 Moti Ramgopal,7 Robert Brennan,8 Mamta K. Jain,9 Amit Khatri,3 Melannie Co,3 Karmin Robinson-Morgan,3 Yiran B. Hu,3
Linda M. Fredrick,3 Nancy S. Shulman,3 Michael Saag,10 David Wyles11
1Ruane Medical & Liver Health Institute, Los Angeles, CA, USA; 2Ruth M. Rothstein CORE Center, Chicago, IL, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Quest Clinical Research, San Francisco, CA, USA; 5AIDS Healthcare Foundation, Beverly Hills, CA, USA; 6St Michael's Medical Center, Newark, NJ, USA; 7Midway Immunology and Research Center, Fort Pierce, FL, USA; 8Infectious Diseases Associates of Central Virginia, Lynchburg, VA, USA; 9UT Southwestern Medical Center, Dallas, TX, USA; 10Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL, USA; 11University of California San Diego, La Jolla, CA, USA
|
| |
|
|
|
|
|
